Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

NCT03061539 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT03061539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03061539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 6, 2018
Completion date
June 30, 2027
Enrollment
380 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer